Morgan Stanley Maintains Hologic(HOLX.US) With Hold Rating, Maintains Target Price $84
A Quick Look at Today's Ratings for Hologic(HOLX.US), With a Forecast Between $84 to $95
Hologic's Strategic Advancements and Robust Market Position Earns 'Buy' Rating Despite Conservative Outlook
Hologic Price Target Raised to $90.00/Share From $84.00 by UBS
Hologic Is Maintained at Overweight by JP Morgan
Hologic Analyst Ratings
Raymond James Adjusts Price Target on Hologic to $95 From $93, Maintains Outperform Rating
RBC Capital Maintains Hologic(HOLX.US) With Hold Rating, Raises Target Price to $89
Needham Maintains Hologic(HOLX.US) With Buy Rating, Maintains Target Price $90
Hologic's Strong Performance and Future Growth Prospects Justify Buy Rating
RBC Capital Maintains Hologic(HOLX.US) With Hold Rating, Raises Target Price to $86
Morgan Stanley Maintains Hologic(HOLX.US) With Hold Rating, Maintains Target Price $84
Hologic (HOLX) Gets a Hold From Morgan Stanley
J.P. Morgan Maintains Hologic(HOLX.US) With Buy Rating, Cuts Target Price to $92
Hologic Analyst Ratings
Needham Maintains Hologic(HOLX.US) With Buy Rating, Maintains Target Price $90
Hologic's Strategic Acquisition of Gynesonics Bolsters Market Position: A Buy Rating by Michael Matson
JPMorgan Adjusts Hologic Price Target to $92 From $95, Maintains Overweight Rating
Buy Rating Maintained for Hologic Amidst Recovery and Strong Capital Management
Hologic Price Target Cut to $90.00/Share From $95.00 by Leerink Partners